Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its ...

Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

Arvinas, Inc. reported positive topline results from its Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings aimed at treating metastatic breast cancer. The company ...

Despite reporting positive topline results from the Phase 3 VERITAC-2 trial and presenting promising data for its neuroscience program, the clinical-stage biotechnology firm’s decision to re ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Reported positive topline data for VERITAC-2, the Phase 3 pivotal 2L+ trial of monotherapy vepdegestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 ...

Shares of Arvinas tumbled 53% to $8.30 on March 11 after it reported results from the Veritac-2 Phase 3 trial of vepdegestrant. Arvinas and Pfizer have said the results were positive and that the ...